Mild, Moderate and Severe Renal Impairment Study

Study identifier:RDEA3170-108

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

A Phase 1, Single-Dose, Open Label, Pharmacokinetic and Pharmacodynamic Study of RDEA3170 in Adult Male Subjects with Mild, Moderate, and Severe Renal Impairment

Medical condition

Gout

Phase

Phase 1

Healthy volunteers

No

Study drug

RDEA3170

Sex

Male

Actual Enrollment

32

Study type

Interventional

Age

18 Years - 85 Years

Date

Study Start Date: 01 Aug 2014
Primary Completion Date: 01 Oct 2015
Estimated Study Completion Date: 01 Jan 2016

Study design

Allocation: Randomized
Endpoint Classification: Pharmacokinetics/dynamics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Basic Science

Verification:

Verified 01 Nov 2015 by Ardea Biosciences, Inc.

Sponsors

Ardea Biosciences, Inc.

Collaborators

-

Inclusion and exclusion criteria